Log in
NASDAQ:ADIL

Adial Pharmaceuticals Stock Forecast, Price & News

$1.21
0.00 (0.00 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.20
Now: $1.21
$1.39
50-Day Range
$1.21
MA: $1.44
$1.92
52-Week Range
$1.00
Now: $1.21
$3.17
Volume1.04 million shs
Average Volume443,031 shs
Market Capitalization$16.41 million
P/E RatioN/A
Dividend YieldN/A
Beta0.83
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADIL
CUSIPN/A
Phone434-422-9800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.69 per share

Profitability

Net Income$-8,590,000.00

Miscellaneous

Employees3
Market Cap$16.41 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$1.21
0.00 (0.00 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADIL News and Ratings via Email

Sign-up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions

How has Adial Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Adial Pharmaceuticals' stock was trading at $1.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADIL shares have decreased by 10.4% and is now trading at $1.21.
View which stocks have been most impacted by COVID-19
.

When is Adial Pharmaceuticals' next earnings date?

Adial Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Adial Pharmaceuticals
.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced its quarterly earnings data on Thursday, August, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter.
View Adial Pharmaceuticals' earnings history
.

Are investors shorting Adial Pharmaceuticals?

Adial Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 514,800 shares, an increase of 97.6% from the August 15th total of 260,500 shares. Based on an average trading volume of 966,000 shares, the days-to-cover ratio is presently 0.5 days.
View Adial Pharmaceuticals' Short Interest
.

Who are some of Adial Pharmaceuticals' key competitors?

What other stocks do shareholders of Adial Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), AIM ImmunoTech (AIM), Aytu Bioscience (AYTU), T2 Biosystems (TTOO), Acasti Pharma (ACST), Biocept (BIOC), Inpixon (INPX) and Tandem Diabetes Care (TNDM).

Who are Adial Pharmaceuticals' key executives?

Adial Pharmaceuticals' management team includes the following people:
  • Mr. William B. Stilley III, M.B.A., MBA, CEO, Pres, Sec., Treasurer & Director (Age 51)
  • Prof. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsych, Founder & Chief Medical Officer (Age 59)
  • Mr. Joseph M. Truluck M.B.A., MBA, CFO & COO (Age 41)
  • Ms. Monika Z. Rogozinska, Chief Devel. Officer
  • Mr. Alex Lugovoy, Head of Strategy

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

Who are Adial Pharmaceuticals' major shareholders?

Adial Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank of America Corp DE (1.12%). Company insiders that own Adial Pharmaceuticals stock include Bankole A Johnson, James W Jr Newman and William B Stilley III.
View institutional ownership trends for Adial Pharmaceuticals
.

Which institutional investors are buying Adial Pharmaceuticals stock?

ADIL stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE. Company insiders that have bought Adial Pharmaceuticals stock in the last two years include Bankole A Johnson, James W Jr Newman, and William B Stilley III.
View insider buying and selling activity for Adial Pharmaceuticals
.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $1.21.

How big of a company is Adial Pharmaceuticals?

Adial Pharmaceuticals has a market capitalization of $16.41 million. Adial Pharmaceuticals employs 3 workers across the globe.

What is Adial Pharmaceuticals' official website?

The official website for Adial Pharmaceuticals is www.adialpharma.com.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company can be reached via phone at 434-422-9800 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.